Could This Vaccine Change Global Health?

An experimental pill that uses live, weakened Shigella bacteria just blocked about nine out of ten volunteers from getting violent diarrhea on purpose.

Story Snapshot

A live oral Shigella sonnei vaccine called WRSs2 showed about 89% protection in a phase 2 challenge trial in healthy U.S. adults.
No vaccine-related serious adverse events were reported, but a handful of strong reactions forced the team to cut the dose.
A single dose looked even better on paper, with zero shigellosis cases in that group during the study window.
Real-world protection for children in poor countries—the people who need it most—still remains a big unanswered question.

A dangerous old disease meets a new kind of pill

Shigella is not a trendy disease, but it quietly sends hundreds of thousands of young children to early graves every year, mostly through filthy water and food that cause explosive diarrhea. Doctors have long depended on antibiotics to save the worst cases, yet more Shigella strains now shrug off common drugs and spread in crowded cities and refugee camps. That rising resistance turns an age-old stomach bug into a modern public health time bomb.

Researchers have chased a Shigella vaccine for decades and failed, especially with shots that needed to work in tiny children in poor settings. The WRSs2 pill takes a different tack. It uses live, weakened Shigella sonnei bacteria with key genes removed so they cannot spread well or release normal levels of toxins. Swallowing this “training bug” aims to teach the gut’s immune system to spot and crush the real thing before it causes invasive diarrhea.

What the human challenge trial really showed

The latest phase 2 trial used what scientists call a controlled human infection model, which means volunteers first got vaccine or placebo, then were later fed a known dose of fully virulent Shigella sonnei strain 53G to see who got sick. Among adults who received two doses of WRSs2, only 3 out of 34 developed shigellosis, compared with 21 out of 26 in the placebo group. That difference translates to an estimated 89% vaccine efficacy.

One detail that caught scientists’ eyes is the single-dose arm. In that group, not a single vaccinated participant developed shigellosis during the challenge period, giving a calculated efficacy of 100%, though with wide uncertainty because of the small sample size. Researchers also measured antibodies in blood and gut samples and found strong responses after vaccination that matched the protection pattern, suggesting the vaccine is hitting the immune system in the right place.

The safety story: strong but short-lived punches

On the safety side, WRSs2 has a decent but not perfect record so far. In an earlier phase 1 trial, both WRSs2 and its cousin WRSs3 were generally well tolerated over several dose levels, with most diarrhea cases rated mild and not disruptive to daily life. In the newer phase 2 challenge trial, no vaccine-related serious adverse events or deaths occurred, which is the key safety line regulators and parents both care most about.

The fine print tells a more mixed story. Six vaccine recipients had grade 3 adverse events after vaccination, strong enough to trigger two meetings of the trial’s data safety monitoring board and a protocol change that lowered the dose and tightened who could enroll. These reactions stopped on their own and did not lead to long-term harm, but they show this is not a sugar pill. Getting strong immunity from a live gut vaccine sometimes means accepting short, sharp side effects.

The gap between lab success and real-world impact

The trial’s volunteers were healthy adults in the United States, watched closely, and then challenged with one lab strain under controlled conditions. That setting is ideal for measuring cause and effect, yet it is far from life in rural Africa or South Asia where kids face constant exposure, malnutrition, other infections, and a mix of Shigella strains. Vaccine trials for other gut infections often look fantastic in these human challenge models, then lose steam when tested in crowded villages.

From a conservative, common-sense view, the smart move is clear. The data show WRSs2 is real medicine, not hype: it prevents disease in a tough test and shows no serious safety red flags so far. But the job is only half done. Before rich nations or global agencies push this pill as a silver bullet, researchers must run full field trials in the very places where children die from Shigella every day, including those under five and people with weak immune systems.

Who controls the data and why it matters

One more wrinkle should matter to anyone who cares about trust in public health. The main sponsor, a large drug company, holds the complete clinical study report and asks outside researchers to request it by email, instead of posting all details openly. That gatekeeping does not mean the numbers are wrong, but it slows independent review and honest debate. Given the lack of a strong public “Side B,” the burden falls on the sponsor and regulators to invite scrutiny, not avoid it.